Omegaven

Omegaven, the active ingredient in Omegaven, is a lipid emulsion presented as an unspecified strength intravenous emulsion for intravenous use. It provides essential omega‑3 fatty acids and calories to patients requiring parenteral lipid supplementation, such as those with essential fatty acid deficiency or parenteral nutrition‑associated liver disease.

GNH USA supplies Omegaven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Omegaven is used in clinical nutrition to address lipid needs and related metabolic conditions. - Parenteral nutrition lipid supplementation: supplies calories and essential omega‑3 fatty acids to patients receiving total parenteral nutrition. - Essential fatty acid deficiency: prevents and treats deficiency in patients unable to obtain fatty acids enterally. - Parenteral nutrition‑associated liver disease: helps manage liver dysfunction linked to long‑term parenteral nutrition. - Severe hypertriglyceridaemia requiring fish‑oil based support: provides a fish‑oil lipid source for patients with high triglycerides who need lipid infusion.

Common Side Effects: - Fever or chills during infusion. - Mild infusion‑site erythema or pain. - Transient elevation of liver enzymes. - Mild hypertriglyceridaemia. - Slight thrombocytopenia.

Serious or Rare Side Effects: - Fat overload syndrome leading to organ dysfunction. - Anaphylactic or severe allergic reactions. - Severe hypertriglyceridaemia with pancreatitis risk. - Coagulopathy or bleeding complications. - Infections related to lipid‑rich medium.

Before initiating Omegaven, clinicians should consider several safety measures. - Monitor triglyceride levels: check serum triglycerides regularly during therapy. - Assess liver function: perform baseline and periodic liver enzyme tests. - Allergy screening: avoid use in patients with known fish or egg phospholipid hypersensitivity. - Caution in severe hyperlipidaemia: weigh benefits against risk of fat overload. - Adjust in metabolic impairment: consider dose modification for hepatic or renal dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Omegaven may interact with other agents that affect lipid metabolism or coagulation. Major Interactions (Avoid): - Concurrent lipid emulsions: risk of cumulative fat overload. - Propofol infusion: excessive lipid load may precipitate hypertriglyceridaemia. - High‑dose anticoagulants: potential for enhanced bleeding. Moderate Interactions (Monitor Closely): - Fibrates or niacin: may amplify triglyceride‑lowering effects, requiring monitoring. - Statins: combined use may increase risk of muscle toxicity. - Immunosuppressants: monitor for altered drug levels due to changes in plasma protein binding.